6xcf
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with noncovalent inhibitor 59== | ==Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with noncovalent inhibitor 59== | ||
| - | <StructureSection load='6xcf' size='340' side='right'caption='[[6xcf]]' scene=''> | + | <StructureSection load='6xcf' size='340' side='right'caption='[[6xcf]], [[Resolution|resolution]] 1.68Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XCF OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6XCF FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6xcf]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/"bacillus_botulinus"_van_ermengem_1896 "bacillus botulinus" van ermengem 1896]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XCF OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6XCF FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6xcf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xcf OCA], [http://pdbe.org/6xcf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6xcf RCSB], [http://www.ebi.ac.uk/pdbsum/6xcf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6xcf ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=UZP:(3R)-3-(2,4-dichlorophenyl)-N~1~-hydroxy-N~5~-pentylpentanediamide'>UZP</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">botA, atx, bonT ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=1491 "Bacillus botulinus" van Ermengem 1896])</td></tr> | ||
| + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Bontoxilysin Bontoxilysin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.24.69 3.4.24.69] </span></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6xcf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xcf OCA], [http://pdbe.org/6xcf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6xcf RCSB], [http://www.ebi.ac.uk/pdbsum/6xcf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6xcf ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/BXA1_CLOBO BXA1_CLOBO]] Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane to the secretory vesicle protein SV2. It binds directly to the largest luminal loop of SV2A, SV2B and SV2C. It is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-|-Arg-198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure. | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Botulinum neurotoxins have remarkable persistence ( approximately weeks to months in cells), outlasting the small-molecule inhibitors designed to target them. To address this disconnect, inhibitors bearing two pharmacophores-a zinc binding group and a Cys-reactive warhead-were designed to leverage both affinity and reactivity. A series of first-generation bifunctional inhibitors was achieved through structure-based inhibitor design. Through X-ray crystallography, engagement of both the catalytic Zn(2+) and Cys165 was confirmed. A second-generation series improved on affinity by incorporating known reversible inhibitor pharmacophores; the mechanism was confirmed by exhaustive dialysis, mass spectrometry, and in vitro evaluation against the C165S mutant. Finally, a third-generation inhibitor was shown to have good cellular activity and low toxicity. In addition to our findings, an alternative method of modeling time-dependent inhibition that simplifies assay setup and allows comparison of inhibition models is discussed. | ||
| + | |||
| + | Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.,Lin L, Olson ME, Sugane T, Turner LD, Tararina MA, Nielsen AL, Kurbanov EK, Pellett S, Johnson EA, Cohen SM, Allen KN, Janda KD J Med Chem. 2020 Sep 18. doi: 10.1021/acs.jmedchem.0c01006. PMID:32886509<ref>PMID:32886509</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6xcf" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Bacillus botulinus van ermengem 1896]] | ||
| + | [[Category: Bontoxilysin]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Allen | + | [[Category: Allen, K N]] |
| - | [[Category: Tararina | + | [[Category: Tararina, M A]] |
| + | [[Category: Covalent inhibitor]] | ||
| + | [[Category: Hydroxamate]] | ||
| + | [[Category: Toxin]] | ||
| + | [[Category: Toxin-inhibitor complex]] | ||
Revision as of 07:44, 30 September 2020
Structure of the C. botulinum neurotoxin serotype A light chain protease in complex with noncovalent inhibitor 59
| |||||||||||
